TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03682562

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA Integrity Index
Description: This test will be performed for ALL three groups:~Sample collection:~Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.~DNA integrity analysis:~The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones.

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA Integrity Index
Description: This test will be performed for ALL three groups:~Sample collection:~Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.~DNA integrity analysis:~The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones.

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA Integrity Index
Description: This test will be performed for ALL three groups:~Sample collection:~Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.~DNA integrity analysis:~The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones.
Study: NCT04526210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 will be administered orally as a single dose as 4 x 15 mg enteric-coated tablets with 240 milliliters of water (fasting), for a total dose of 60 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride
Description: Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride
Description: Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).
Study: NCT04191980

Intervention type: OTHER
Intervention: Comparison of prostate multi-zone segmentation obtained with an automatic deep learning-based algorithm and two expert radiologists
Description: The algorithm is used to perform a multizone segmentation of the prostate including delineation of : the whole prostate contours, the transition zone contours, the anterior fibromuscular stroma.~The contours is independently corrected by 2 radiologists. The corrected contours of the different zones will be stored and for each zone 6 different metrics will be used to evaluate the difference between the initial and corrected contours:~* Mean Mesh Distance: Average Boundary Distance (ABD) for each point of the reference segmentation. The distance to the closest point of the compared segmentation is first computed. Then the average of all these distances is computed and gives the ABD~* General Hausdorff distance (HD)~* 95% percentile (P) of the HD and the 95th (P) of the asymmetric HD distribution~* 95% HD modified (HD95_1): different approach by first computing the 95th (P) of the asymmetric HD then taking the maximum~* Dice coefficient~* Difference in volumes

Intervention type: OTHER
Intervention: Comparison of prostate multi-zone segmentation obtained with an automatic deep learning-based algorithm and two expert radiologists
Description: The algorithm is used to perform a multizone segmentation of the prostate including delineation of : the whole prostate contours, the transition zone contours, the anterior fibromuscular stroma.~The contours is independently corrected by 2 radiologists. The corrected contours of the different zones will be stored and for each zone 6 different metrics will be used to evaluate the difference between the initial and corrected contours:~* Mean Mesh Distance: Average Boundary Distance (ABD) for each point of the reference segmentation. The distance to the closest point of the compared segmentation is first computed. Then the average of all these distances is computed and gives the ABD~* General Hausdorff distance (HD)~* 95% percentile (P) of the HD and the 95th (P) of the asymmetric HD distribution~* 95% HD modified (HD95_1): different approach by first computing the 95th (P) of the asymmetric HD then taking the maximum~* Dice coefficient~* Difference in volumes
Study: NCT02835261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Mild sleep restriction (-1.5 h/night) over a period of 6 weeks
Study: NCT02017964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Optional ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01408199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5 mg daily will be administered until the achievement of complete response, and then tapered progressively according to clinical response
Study: NCT00352690

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel poliglumex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel poliglumex

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: RADIATION
Group type: OTHER
Intervention: External beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Study: NCT03336411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: Behavioral weight loss intervention using behavioral counseling focusing on physical activity and a one-size-fits-all, calorie-restricted, diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized mHealth
Description: Behavioral weight loss intervention with personalized dietary recommendations based on machine learning algorithm that integrates gut microbiota, dietary intake, physical activity and various blood parameters to predict postprandial glycemic response.
Study: NCT01848301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: OCT imaging of the LAD coronary artery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Infusion in the coronary artery to study endothelial function

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachial Artery Flow Mediated Dilation
Description: Assess peripheral brachial artery endothelial function
Study: NCT01509300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: On days -10 to -9

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning on day 4 and continuing until blood counts recover

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 2Gy D-6 to D-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/M2 once daily IV on days -8 to -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg IV on day-3 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: begin on 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: begin on 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 on day +21
Study: NCT02324803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: continuous treatment of 800 mg pazopanib once daily until disease progression
Study: NCT04549844

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.~Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.~Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.
Study: NCT02865538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3427080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3427080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3427080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3427080

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for BAY3427080)
Study: NCT04008784

Intervention type: DRUG
Intervention: Crisaborole 2% Topical Application Ointment [EUCRISA]
Description: Ointment

Intervention type: DRUG
Intervention: Crisaborole 2% Topical Application Ointment [EUCRISA]
Description: Ointment

Intervention type: DRUG
Intervention: Triamcinolone Acetonide 0.1% Ointment
Description: Topical Corticosteroid
Study: NCT04709809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retinal Vessel Analyzer recordings with electrocardiographic (ECG) gating
Description: Video recordings of ocular fundus, an analysis of dynamic vessel diameters and putting them in ECG context.
Study: NCT03986177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management Intervention Package
Description: Children will receive basic asthma education, based on the National Heart, Lung, and Blood Institute A Breath of Life asthma education program. Children/caregivers in the intervention arm will also be assigned a designated nurse case manager who will provide home visits and be available via text message and phone-based support throughout follow-up. Intervention components:~* Interactive education and support on use of an asthma action plan~* Locally adapted patient-provider communication tool~* Child-oriented educational materials in comic book format~* Modeling and hands-on practice of inhaler technique (written instructions, in person, video)~* Education regarding environmental trigger abatement~* Patient navigation, home visits, and goal setting support from nurse manager
Study: NCT03960970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg
Description: Additional IV Azithromycin 500 mg to Standard Prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefoxin 2g
Description: Standard Prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefoxin 2g
Description: Standard Prophylaxis
Study: NCT02539589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BART
Description: BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: Healthy Living is a knowledge-based intervention that intends to provide one HIV information-only session and seven sessions on nutrition, healthy eating, body image, and exercise. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
Study: NCT04335578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zampilimab
Description: Participants will receive zampilimab (UCB7858) at pre-specified time-points.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo (PBO) at pre-specified time-points.
Study: NCT03309709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous progesterone
Description: 25mg daily for 7 days
Study: NCT01900730

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient takes placebo capsule 3 times a day by mouth for 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid (VPA)
Description: Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completed at baseline, weeks 2, 6, and 10.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, weeks 2, 6, and 10.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pill Diary
Description: Patient given a pill diary to record the time each dose taken.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pill Diary
Description: Patient given a pill diary to record the time each dose taken.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Drainage Diary
Description: Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drainage Diary
Description: Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
Study: NCT03985670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teripalimab plus chemotherapy
Description: teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy plus teripalimab
Description: paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1 teripalimab 240mg d3
Study: NCT02222155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
Study: NCT03202914

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual protein and phosphorus diet
Description: Diet intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low protein and phosphorus diet
Description: Diet intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very low protein and phosphorus
Description: Diet intervention
Study: NCT01627457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Exercise (GEx) system
Description: 30 CAD patients will wear the GEx system while they are trained during inpatient cardiac rehabilitation (phase II) in order to evaluate accuracy and safety of data like heart rate, breathing, ECG three times a week for about three weeks. In a second step these patients train at home (phase III) in order to evaluate practicability and technical problems of the GEx device three times a week for about three weeks.
Study: NCT02201225

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplement with micronutrient
Description: Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Nutritional supplement without micronutrient
Description: Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve
Study: NCT01374919

Intervention type: DRUG
Group type: OTHER
Intervention: ferumoxytol
Description: IV administration of 1020 mg of ferumoxytol in 15 minutes
Study: NCT03006445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Study: NCT02243930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable distal attachment
Study: NCT02445456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sienna+ injection
Description: Endoscopic injection of magnetic tracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sienna+ injection
Description: Endoscopic injection of magnetic tracer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan of pelvis to detect spread of magnetic tracer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery to excise rectal cancer
Description: Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery to excise rectal cancer
Description: Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentimag probe
Description: Probe to detect the previously injected magnetic tracer (Sienna+)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentimag probe
Description: Probe to detect the previously injected magnetic tracer (Sienna+)
Study: NCT01440283

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: IMRT delivery will follow current conventional volume-targeting guidelines, however, appropriate application within the abdomen will be determined by ascertaining intra-abdominal organ motion and the potential for reducing normal tissue dose, while simultaneously increasing dose delivered to target tissues, particularly when dose escalation for gross residual disease is required. Concurrent neuro-hormonal tests, cytokine analyses, functional and morphologic imaging will generate novel data describing the acute and chronic effects of radiotherapy within the abdomen.
Study: NCT03151278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zero-fluoroscopy ablation
Description: Catheter ablation will be performed under the guidance of one kind of three-dimensional navigation system and without fluoroscopic guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fluoroscopy ablation
Description: Catheter ablation will be performed using fluoroscopy plus one kind of three-dimensional navigation system.
Study: NCT02458482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuPAP
Description: The AccuPAP device used by participants will give 2.5mg and 0.5mg nebulized Albuterol and Ipratropium over 5 minutes. Inspiratory and expiratory pressures to be set at 6 and 12 cm H20 respectively. This therapy is repeated at 20 and 40 minutes for a total of three AccuPAP treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol and Ipratropium Continuous Nebulizer
Description: 10mg Albuterol and 1.5mg Ipratropium continuous nebulizer treatment will be administered to a Control group over a one hour period.
Study: NCT03180606

Intervention type: OTHER
Intervention: Multi-disciplinary and personalized primary care
Description: Team-based primary care where nurse, GP, social-worker, physiotherapist, occupational therapist evaluate and give treatment
Study: NCT05877170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitoyletinolamide
Description: Taking a once-daily supplement containing PEA in an oral formulation (tablets), to be taken away from meals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking a placebo in an oral formulation (tablets), to be taken away from meals
Study: NCT02917902

Intervention type: OTHER
Group type: OTHER
Intervention: Food boxes
Description: Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food boxes
Description: Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.
Study: NCT02962297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E softgel
Description: All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).~Height and weight, waist-to-hip ratio Review of diet and exercise
Study: NCT01924078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: metronomic use: capecitabine 500mg/tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aromatase Inhibitors (AIs)
Description: Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.